Analysts have been eager to weigh in on the Healthcare sector with new ratings on Avadel Pharmaceuticals (AVDL – Research Report) and Bioventus (BVS – Research Report).
Avadel Pharmaceuticals (AVDL)
In a report released today, Ami Fadia from Needham reiterated a Buy rating on Avadel Pharmaceuticals, with a price target of $11.00. The company’s shares closed last Friday at $9.16, close to its 52-week high of $10.02.
According to TipRanks.com, Fadia is a 2-star analyst with an average return of
Avadel Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $14.80, which is a 71.3% upside from current levels. In a report issued on March 23, H.C. Wainwright also reiterated a Buy rating on the stock with a $14.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Bioventus (BVS)
According to TipRanks.com, Nowak is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Bioventus has an analyst consensus of Hold, with a price target consensus of $467.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AVDL:
- Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
- Avadel Pharmaceuticals reports Q4 EPS (44c), consensus (27c)
- Avadel Pharmaceuticals 10M share Spot Secondary priced at $8.50
- Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 30
- Avadel Pharmaceuticals Announces Pricing of Public Offering of ADSs and Series B Preferred Shares
